Author (ref) | Population, age (yrs) | Incidence (per 100py) | Clearance | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Any HPV | HR | 16 | 18 | Type of Infection | Unit of clearance | Any HPV | HR | 16 | 18 | ||
Males | |||||||||||
de Pokomandy [38] | HIV + ve MSM, 21–66 | - | - | 13.0 (9.6–17.6) | 5.3 (3.5–8.0) | Prevalent | Per 100py | 14.6 (10.2–21.2) | 24.5 (16.9–35.4) | ||
Nyitray [35] | MSM, 18–70 MSW, 18–70 | 31.1 (TS) (16.6–53.2) 9.7 (7.2–12.8) | 25.4 (14.5–41.2) 4.4 (2.9–6.6) | 5.8 (1.9–13.4) 0.8 (0.2–2.0) | 4.6 (1.2–11.6) 1.1 (0.4–2.3) | Prevalent | % at 6 m- | 57.1 (TS) (50.1–63.8) 70.9 (63.5–77.5) | 55.8 (44.1–67.2) 77.5 (66.0–86.5) | 27.2 (6.0–61.0) 100 (83.9–100) | 62.5 (24.5–91.5) 100 (15.8–100) |
Videla [23] | HIV + ve MSM, 20- > 69 HIV + ve MSW, 20- > 69 | 32.4 (NTS) (23.3–43.7) 7.9 (4.9–15.7) | - | - | - | Prevalent | Per 100py | 12.6 (NTS) (10.2–15.2) 18.4 (12.2–26.5) | - | - | - |
Darwich [20] | HIV + ve MSM, 20- > 69 HIV + ve MSW, 20- > 69 | - | - | 7.1 (5.5–9.5) 5.3 (3.0–8.6) | 3.6 (3.5–5.2) 0.4 (0.1–1.8) | Prevalent | Per 100py | - | 22.4 (17.6–28.1) 18.6 (7.4–38.2) | 31.0 (20.3–45.4) 30.0 (7.8–76.8) | |
Mullins [37] | HIV-ve, 12–18 HIV + ve, 12–18 | 24 (NTS, first) (11–52) 40 (27–61) | 11 (3.4–33) 27 (17–44) | - | - | - | - | - | - | - | - |
Glick [33] | MSM, 16–30 | 46.2 (NTS, unclear) (45.6–46.9) | 36.7 (36.2–37.3) | 12.4 (12.1–12.6) | 5.5 (5.3–5.6) | Prevalent | % at 1 year | 81.3 (TS) (67.4–91.1) | 66.7 (49.0–81.4) | 50.0 (26.0–74.0) | 66.7 (22.3–95.7) |
Hernandez [34] | HIV + ve MSM, mean 45 | 21.3 (TS, total) (17.7–25.4) | 13.3 (10.5–16.6) | 3.5 (1.8–6.1) | 3.7 (2.1–6.1) | - | - | - | - | - | - |
Females | |||||||||||
Sexually active women, 18–44 | 56.3 (NTS, first) (48.5–65.0) | 23.4 (19.2–28.3) | 3.0 (1.8–4.8) | 2.3 (1.2–3.9) | Incident | Per 100py | 89.3 (TS) (67.8–115.4) | 109.9 (83.3–142.4) | 141.2 (73.0–246.7) | 130.0 (47.6–282.8) | |
Moscicki [40] | Sexually active women, 13–21 | - | - | - | - | Prevalent | % at 12 m | - | 29.7 (TS 2 + neg) (19.0–41.7) | 45.0 (27.2–62.1) | 55.6 (21.2–86.3) |
Mullins [37] | HIV-ve women, 12–18 HIV + ve women, 12–18 | 14 (NTS,first) (9.2–22) 30 (24–38) | 5.3 (2.6–11) 12 (8.4–16) | - | - | - | - | - | - | - | - |